Skip to content

Search

National Indigenous Immunisation Research Workshop

You are invited to register to attend the National Indigenous Immunisation Research Workshop 2013: lessons learnt and future directions Workshop.

Experts gather for Aboriginal Immunisation Workshop

Experts in Aboriginal infectious disease research are in Perth this week for the National Indigenous Immunisation Research Workshop (November 7-8).

The science of immunisation: Questions and answers

Common myths about immunisation have been laid to rest in a new booklet written by top immunologists and published by the Australian Academy of Science.

New vaccine could protect against more types of cancer-causing HPV

Trial of new vaccine that could provide women with additional protection against Human Papillomavirus (HPV) types known to cause cervical cancer.

Perth women needed for international cervical cancer study

Perth women are being invited to take part in a global study of an exciting new vaccine that could protect against cervical cancer

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia

We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PApilloma TRIal against Cancer In young Adults.

Changes in thymic regulatory T-cell maturation from birth to puberty: Differences in atopic children

We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In young...

Predominance of nontypeable haemophilus influenzae in children with otitis media

In Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose.

Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance

Concerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted the widespread adoption...

Trivalent influenza vaccine and febrile adverse events in australia, 2010: Clinical features and potential mechanisms

Increased numbers of children presenting with febrile adverse events following trivalent influenza vaccine (TIV) were noted in Australia in 2010.